Laboratoire Tilman has acquired Promogen
The shareholders of Promogen have sold the company to Laboratoire Tilman.
Founded in 1956, Laboratoire Tilman is a Belgium pharmaceutical laboratory specialized in the development, production and marketing of phytotherapy products and is the leader in the field of medicinal plants in Belgium. The company offers a range of more than 100 natural herbal solutions sold in over 30 countries, including best-selling products such as Flexofytol, Sedistress and Antimetil.
Founded in 2012, Promogen is an external independent French pharmaceutical network that promotes, sells and distributes a diverse portfolio, which includes medicines, medical devices, food supplements and cosmetics, through four brands, in the rheumatology, well-being, dermo-cosmetics, wound healing and fertility therapeutic areas. Promogen distributes its products to over 9,000 pharmacies and drugstores in France, through an in-house sales force of approximately 40 representatives.
Oaklins’ team in France acted as advisor to the shareholders of Laboratoire Tilman in this transaction.
Talk to the deal team
Related deals
Leika Medical Equipments Ltd. has been acquired by Angus Capital
The shareholders of Leika Medical Equipments Ltd. have sold the company to Angus Capital.
Learn morePhen’X Technologies has sold a majority stake to Ciclad
The shareholders of Phen’X Technologies have completed a primary majority LBO with private equity fund Ciclad.
Learn moreMedis Medical Imaging and GE HealthCare announce collaboration focused on non-invasive coronary assessments
Medis Medical Imaging Systems B.V., a leading cardiac imaging software company, have completed a strategic investment to further develop its revolutionary non-invasive cardiovascular imaging solution. The company has announced its collaboration with GE HealthCare (Nasdaq: GEHC), a global leader in medical technology, pharmaceutical diagnostics and innovation in digital solutions, to contribute to the advancement of precision care in the diagnosis and treatment of coronary artery disease (CAD).
Learn more